Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases.

ABSTRACT:

Background

Dacomitinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) which is superior to first-generation EGFR TKI in ARCHER 1050. However, the activity of dacomitinib in the central nervous system (CNS) is not known as ARCHER 1050 did not include patients with baseline brain metastases. This study aimed to describe dacomitinib's activity in the CNS in a real-world setting.

Patients and methods

Thirty-two patients who were receiving dacomitinib for advanced non-small-cell lung cancer (NSCLC) with EGFR mutations and brain metastasis were included in this study. Patients who received prior EGFR TKIs were excluded from this trial. Case report forms were collected to determine treatment outcomes.

Results

Among 32 patients

SUBMITTER: Zhang J 

PROVIDER: S-EPMC8671892 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature